UB Paderborn / Katalog / Suche / in CDI

Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling

Antimicrobial agents and chemotherapy, 2015-04, Vol.59 (4), p.2315-2327

2015

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

Clinical pharmacokinetics, 2023-04, Vol.62 (4), p.587-598

2023

Link zum Volltext

Verfügbarkeit prüfen

Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing

Pharmacotherapy, 2010-12, Vol.30 (12), p.1279-1291

2010

Link zum Volltext

Verfügbarkeit prüfen

Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design

Antimicrobial Agents and Chemotherapy, 2013-05, Vol.57 (5), p.2343-2351

2013

Link zum Volltext

Verfügbarkeit prüfen

Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae : pharmacodynamics and morphological changes

International journal of antimicrobial agents, 2017-02, Vol.49 (2), p.224-232

2017

Link zum Volltext

Verfügbarkeit prüfen

Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model

Antimicrobial Agents and Chemotherapy, 2010-05, Vol.54 (5), p.2051-2062

2010

Link zum Volltext

Verfügbarkeit prüfen

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies

Journal of antimicrobial chemotherapy, 2016-11, Vol.71 (11), p.3148-3156

2016

Link zum Volltext

Verfügbarkeit prüfen

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance

Journal of antimicrobial chemotherapy, 2015-05, Vol.70 (5), p.1434-1442

2015

Link zum Volltext

Verfügbarkeit prüfen

New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease

Antimicrobial Agents and Chemotherapy, 2014-03, Vol.58 (3), p.1381-1388

2014

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery

Antimicrobial agents and chemotherapy, 2017-01, Vol.61 (1)

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3453-3456

2012

Link zum Volltext

Verfügbarkeit prüfen

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin

Antimicrobial agents and chemotherapy, 2017-04, Vol.61 (4)

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa

Antimicrobial agents and chemotherapy, 2016-05, Vol.60 (5), p.2870-2880

2016

Link zum Volltext

Verfügbarkeit prüfen

Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy, 2009-01, Vol.53 (1), p.46-56

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Variability beyond That Explained by MICs

Antimicrobial Agents and Chemotherapy, 2013-04, Vol.57 (4), p.1730-1735

2013

Link zum Volltext

Verfügbarkeit prüfen

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators

Antimicrobial agents and chemotherapy, 2015-07, Vol.59 (7), p.4343-4346

2015

Link zum Volltext

Verfügbarkeit prüfen

Moving From Point‐Based Analysis to Systems‐Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria

Clinical pharmacology and therapeutics, 2021-11, Vol.110 (5), p.1196-1206

2021

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes

Clinical pharmacokinetics, 2022-06, Vol.61 (6), p.833-845

2022

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma

Cancer chemotherapy and pharmacology, 2023-02, Vol.91 (2), p.179-189

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Journal of clinical pharmacology, 2021-07, Vol.61 (7), p.901-912

2021

Link zum Volltext

Verfügbarkeit prüfen

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses

Annals of the rheumatic diseases, 2019-02, Vol.78 (2), p.228

2019

Link zum Volltext

Verfügbarkeit prüfen

Optimizing polymyxin antibiotics using combination therapy and mechanism-based models

Ly, Neang S

2014

Link zum Volltext
ProQuest

Translational Modeling of Antibacterial Agents

Systems Pharmacology and Pharmacodynamics, 2016, Vol.23, p.371-402

2016

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Sustainable Energy Potential of Non- Plantation Biomass Resources in Sameakki Meanchey District in Kampong Chhnang Province, Cambodia

International Journal of Environmental and Rural Development, 2013, Vol.4(2), pp.173-178

2013

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing

Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design

Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae : pharmacodynamics and morphological changes

Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance

New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease

Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery

Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa

Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa

Pharmacodynamic Variability beyond That Explained by MICs

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators

Moving From Point‐Based Analysis to Systems‐Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria

Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses

Optimizing polymyxin antibiotics using combination therapy and mechanism-based models

Translational Modeling of Antibacterial Agents

Assessment of Sustainable Energy Potential of Non- Plantation Biomass Resources in Sameakki Meanchey District in Kampong Chhnang Province, Cambodia

Suchergebnisse filtern